to the moon shot effort, which we participated in and met with vice president biden's staff with greg simon yesterday. we have been activelyprocess. it's fantastic for supporting awareness and enhancing collaboration between the various cancer centers both here in the united states and worldwide. we are appreciative of the support that the moon shot brings. there are other enablers that the moon shot highlights like how do all patients have access to the treatments if they can't come to seattle? we need to make sure there's access and ensure they are trackable from a health care cost effective stand. they can be expensive. are they worth the value? if you are curing people, yes, they are cost effective. we need to solve for those challenges in a context where oncology costs are spiraling upwards. there are a number of policy issues to address. we are grateful to the fda for their support of development of the treatments where you can move drugs forward through a mechanism they developed called breakthrough status. you have a drug that has a dramatic effect. they help facilitate the developm

that was greg simon just mentioned the long lasting nature of some initiative started late in administration. it looks like dr. califf will fall that i believe a set up areas and initiatives that will be affordable into the next decade. so please join in welcoming and listening to commissioner califf. [applause] >> thanks a bunch and it's great to be here. it's funny, i phone goes off just as i'm getting up. it's my office. well, i guess i will call them back after this. if it's important they will call back. i do want to keep my remarks brief because i think i learned in this job it's better to have interchange with the audience than it is to just give another rendition of priorities. i do think based on a number of things that happened recently, it is worth emphasizing the bigger picture priorities that need to be kept in mind as we deal with what really is an amazing explosion of biotechnology. as i think about my job, i would urge you to consider each part of fda that may be important to you to think about the bigger picture a little bit because we've got to make all this fit together. f

>> joining me the man had 25 year headstart michael milliken chairman of the institute with us greg simoncancer moon shot task force good to see you -- >> great to be here. >> the reason that i mentioned that mike is because we go back, and i know it has got to be 20, 25 years ago when i first attended a faster curious meeting that you hosted i was aastoundeded by people profit nonprofit doctors all over the world you said i am not going to give you any money i am not giving you funding unless you share your research. wow. what a major result that created. >> it has. and the partnership of government agencies nih, cdc, fda, many others with biopharma as i say every time we are together and to your fans watching us today, more than 50% of all economic growth has come from health medical research greatest achievement ever occurred inings as i havization extension of life we sometimes forget the start of the 20th century life was 31 years today mid 70s planet amazing thing occurred, and the concept that the best investment we can make is that investment in bioscience propel longer, healthier

we just met with vice president biden's staff, with greg simon yesterday.we've been actively involved in that process. it's a fantastic mechanism for supporting awareness and for enhancing and supporting collaboration between the various cancer centers both here in the united states and worldwide. so we're very appreciative of the support that the moon shot brings. there are also other enablers that the moon shot highlighted for instance how do we make sure all patients have access to the sophisticated treatments if they can't come to seattle, for example? we need to make sure there is access. we need to insure these are trackable from a health care cost effective perspective. these can be very expensive treatments. are they worth the value? we would argue if you're curing people, yes, those are cost effective, but we need to solve for the challenges in a context where oncology costs are rapidly spiraling upward. there are a number of policy issues we need to address. we're also very grateful to the fda for their support of rapid development of these new tr